<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577576</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2012/APM-01</org_study_id>
    <secondary_id>2012-A00475-38</secondary_id>
    <nct_id>NCT01577576</nct_id>
  </id_info>
  <brief_title>Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes</brief_title>
  <acronym>MediaSport</acronym>
  <official_title>Morphological, Biomechanical and Functional Properties of the Arterial Wall of Athletes: Impact and Consequences of Mechanical Stress on the Cardiovascular Adaptations of Peripheral Arterial Calcifications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to obtain data for the integrated analysis of&#xD;
      morphological, functional and biomechanical parameters pertaining to lower limb arteries in&#xD;
      various categories of elite athletes (without cardiovascular risk and practicing high- or&#xD;
      low-impact aerobic activities which preferentially implicate lower limb activity) as compared&#xD;
      to (each other and to) sedentary controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives of this study are:&#xD;
&#xD;
      A. Determine the presence and extent of intima-media calcifications in athletes B. Determine&#xD;
      the relationship between these calcifications and the level, length and intensity of sports&#xD;
      activity.&#xD;
&#xD;
      C. Determine the relationship between these properties and calcification of the arterial wall&#xD;
      D. Analyze the relationship between the type of sports activity and properties of the&#xD;
      arterial wall.&#xD;
&#xD;
      E. Examine the relationship between the properties of the arterial wall and peripheral&#xD;
      perfusion pressures.&#xD;
&#xD;
      F. Examine the relationship between the properties of the arterial wall, changes in&#xD;
      afterload, morphology and systolic heart function.&#xD;
&#xD;
      G. Analyze the relationships between the parameters characterizing the arterial wall and&#xD;
      muscle mass of the lower limbs.&#xD;
&#xD;
      H. Analyze the relationship between the presence of intramural calcification and bone density&#xD;
      determined by densitometry.&#xD;
&#xD;
      I. Analyze the relationship between the presence of intramural calcification and dietary&#xD;
      protein intake and calcium.&#xD;
&#xD;
      J. Compare indices of pressure at the ankle and toe, depending on the extent of&#xD;
      calcification.&#xD;
&#xD;
      K. Create a collection of biological samples (serum).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion curve too slow.&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence / absence of intra parietal calcification of lower limb arteries</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of intra parietal calcification of lower limb arteries</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>Score ranging from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inner diameter of the intima-media of the common femoral artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outer diameter of the intima-media of the common femoral artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inner diameter of the intima-media of the superficial femoral artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outer diameter of the intima-media of the superficial femoral artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inner diameter of the intima-media of the common carotid artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outer diameter of the intima-media of the common carotid artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the intima-media of the common femoral artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the intima-media of the superficial femoral artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the intima-media of the common carotid artery (mm)</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local parietal compliance of the superficial femoral artery</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>mm^2/mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance of the carotid artery</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>mm^2/mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distensibility of the carotid artery</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>mmHg^-1*10^-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial wave velocity in lower limb</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>m/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial wave velocity in upper limb</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>m/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium-dependent vasorelaxation in the femoral artery</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postischemic vasomotor response at the (skin) microcirculatory level</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic pressure index at the ankle</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>relative units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic pressure index for the big toe</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>relative units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac afterload index</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>g/cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing systolic function: the stroke volume</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing systolic function: cardiac output</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>l/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing systolic function: peripheral vascular resistance</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>Pa.s/m^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing systolic function: fractional shortening</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing systolic function: speed of the S-wave according to tissue Doppler</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>cm.s-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing systolic function: global longitudinal strain</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular-arterial coupling</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>relative units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: transmitral E wave velocity</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>cm/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: transmitral A wave velocity</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>cm/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: transmitral E wave velocity / transmitral A wave velocity</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>relative units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: maximum Em wave velocity according to tissue Doppler</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>cm/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: maximum Am wave velocity according to tissue Doppler</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>cm/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: transmitral E wave velocity / maximum Em wave velocity according to tissue Doppler</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>relative units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters analyzing diastolic function: early diastolic strain-rate</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>s^-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Years of athletic training</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hours of athletic training per week</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>h/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best performance in the last 6 months</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower limb muscle mass</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>g/cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary protein intake</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>g/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary protein intake</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>% calories per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary calcium intake</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>mg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum protein</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorus</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum parathyroid hormone</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>ng/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vitamin D2</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>µg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vitamin D3</measure>
    <time_frame>Baseline (Day 0; transversal study)</time_frame>
    <description>µg/l</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Monckeberg Medial Calcific Sclerosis</condition>
  <arm_group>
    <arm_group_label>Upper-body athletes</arm_group_label>
    <description>This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower-body athletes</arm_group_label>
    <description>This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedentary volunteers</arm_group_label>
    <description>This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A non-fasting venous blood sample is required for the following cofactors:&#xD;
&#xD;
        -  serum protein&#xD;
&#xD;
        -  serum calcium&#xD;
&#xD;
        -  phosphorus&#xD;
&#xD;
        -  PTH&#xD;
&#xD;
        -  Vitamin D2 and D3&#xD;
&#xD;
      Left-over serum will be stored in the Nîmes University Hospital &quot;Sérotheque&quot; (serum&#xD;
      collection).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is composed of three groups of healthy volunteers: (1) high impact&#xD;
        lower-limb sports (marathon or trail); (2) low-impact lower-limb sports and (3) sedentary&#xD;
        volunteers. All volunteers are between the ages of 25 and 40.&#xD;
&#xD;
        The groups will be matched by age and sex. Athletic groups will be matched according to&#xD;
        years of intensive practice and hours of training.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for athletic and sedentary volunteers:&#xD;
&#xD;
          -  The volunteer must have given his/her informed and signed consent&#xD;
&#xD;
          -  The volunteer must be insured or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Volunteers without cardiovascular disease, glucose regulation disorders or known renal&#xD;
             disease&#xD;
&#xD;
        Inclusion Criteria for athletic volunteers only:&#xD;
&#xD;
          -  Ongoing athletic activity for the past 10 years&#xD;
&#xD;
          -  Athletic activity at the regional level for the past 5 years&#xD;
&#xD;
          -  Practices one of the three following sports: marathon, trail running, cycling.&#xD;
&#xD;
        Exclusion Criteria for athletic and sedentary volunteers:&#xD;
&#xD;
          -  The volunteer is participating in another study&#xD;
&#xD;
          -  The volunteer is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  The volunteer is under judicial protection, under tutorship or curatorship&#xD;
&#xD;
          -  The volunteer refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to correctly inform the volunteer&#xD;
&#xD;
          -  The volunteer is pregnant, parturient, or breastfeeding&#xD;
&#xD;
          -  Tobacco use&#xD;
&#xD;
          -  Contraindications for the practice of physical activity (joint, heart or other)&#xD;
&#xD;
          -  Intercurrent pathology&#xD;
&#xD;
          -  First degree family history of cardiovascular disease&#xD;
&#xD;
          -  Known dyslipidemia (including cholesterol)&#xD;
&#xD;
          -  Glucose tolerance abnormalities (prediabetes or diabetes)&#xD;
&#xD;
          -  Treatment with certain drugs used for treating erectile dysfunction: Sildefanil&#xD;
             (Viagra), Tadalafil (Cialis), Vardenafil (Levitra) and yohimbine (Yohimbine Houde and&#xD;
             Yocoral)&#xD;
&#xD;
        Exclusion Criteria for sedentary volunteers only:&#xD;
&#xD;
          -  More than two hours of athletic activity per week&#xD;
&#xD;
          -  History of intense athletic training&#xD;
&#xD;
          -  Body mass index &gt;= 25 kg/m^2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonia Perez Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université d'Avignon, Faculté des Sciences</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Athletes</keyword>
  <keyword>Sedentary volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Monckeberg Medial Calcific Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

